Sciele Pharma, Inc. and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel Used in Combination with Stimulants to Treat ADHD

ATLANTA & DURHAM, N.C.--(BUSINESS WIRE)--Sciele Pharma, a Shionogi Company, and Addrenex Pharmaceuticals, Inc. today announced that a preliminary analysis showed positive results from a second Phase III trial of Clonicel®, demonstrating that the combination of Clonicel with stimulants provided statistically significant improvements in ADHD symptoms compared to stimulant used alone.

Back to news